[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2024

February 2024 | 85 pages | ID: A745521673F4EN
APO Research

US$ 2,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS) Treatment.

The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Amyotrophic Lateral Sclerosis (ALS) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • Mylan Pharma
  • Apotex
  • Glemark Generics
  • Covis Pharma
  • Sun Pharma
  • Lunan Pharma
Product Type Insights

Global markets are presented by Amyotrophic Lateral Sclerosis (ALS) Treatment type, along with growth forecasts through 2030. Estimates on revenue are based on the price in the supply chain at which the Amyotrophic Lateral Sclerosis (ALS) Treatment are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).

Amyotrophic Lateral Sclerosis (ALS) Treatment segment by Type
  • Riluzole
  • Edaravone (Radicava)
  • Other
Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).

This report also outlines the market trends of each segment and consumer behaviors impacting the Amyotrophic Lateral Sclerosis (ALS) Treatment market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Amyotrophic Lateral Sclerosis (ALS) Treatment market.

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application
  • Hospital
  • Drugs Store
  • Other
Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2019-2030.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.
  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA
Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Amyotrophic Lateral Sclerosis (ALS) Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Amyotrophic Lateral Sclerosis (ALS) Treatment industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.
1 PREFACE

1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
  1.5.1 Secondary Sources
  1.5.2 Primary Sources

2 MARKET OVERVIEW

2.1 Product Definition
2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
  2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
  1.2.2 Riluzole
  1.2.3 Edaravone (Radicava)
  1.2.4 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment by Application
  2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
  2.3.2 Hospital
  2.3.3 Drugs Store
  2.3.4 Other
2.4 Assumptions and Limitations

3 AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT BREAKDOWN DATA BY TYPE

3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2019-2024)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2025-2030)

4 AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT BREAKDOWN DATA BY APPLICATION

4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Application (2019-2024)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2019-2024)

5 GLOBAL GROWTH TRENDS

5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2019-2030)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
  5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2019 VS 2023 VS 2030
  5.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Region (2019-2024)
  5.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2025-2030)
5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
  5.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
  5.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
  5.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
  5.3.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

6.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue
  6.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2019-2024)
  6.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2019-2024)
6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Players Ranking, 2022 VS 2023 VS 2024
6.3 Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment Head office and Area Served
6.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Product Type & Application
6.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players, Date of Enter into This Industry
6.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

7.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
7.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
7.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
7.5 United States
7.6 Canada

8 EUROPE

8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
8.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries

9 ASIA-PACIFIC

9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
9.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia

10 LATIN AMERICA

10.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
10.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
10.4 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
9.4 Mexico
9.5 Brazil

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2019-2030)
11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2019-2024)
11.4 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2025-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE

12 PLAYERS PROFILED

11.1 Mitsubishi Tanabe Pharma
  11.1.1 Mitsubishi Tanabe Pharma Company Detail
  11.1.2 Mitsubishi Tanabe Pharma Business Overview
  11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.1.5 Mitsubishi Tanabe Pharma Recent Development
11.2 Sanofi
  11.2.1 Sanofi Company Detail
  11.2.2 Sanofi Business Overview
  11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.2.5 Sanofi Recent Development
11.3 Mylan Pharma
  11.3.1 Mylan Pharma Company Detail
  11.3.2 Mylan Pharma Business Overview
  11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.3.5 Mylan Pharma Recent Development
11.4 Apotex
  11.4.1 Apotex Company Detail
  11.4.2 Apotex Business Overview
  11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.4.5 Apotex Recent Development
11.5 Glemark Generics
  11.5.1 Glemark Generics Company Detail
  11.5.2 Glemark Generics Business Overview
  11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.5.5 Glemark Generics Recent Development
11.6 Covis Pharma
  11.6.1 Covis Pharma Company Detail
  11.6.2 Covis Pharma Business Overview
  11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.6.5 Covis Pharma Recent Development
11.7 Sun Pharma
  11.7.1 Sun Pharma Company Detail
  11.7.2 Sun Pharma Business Overview
  11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.7.5 Sun Pharma Recent Development
11.8 Lunan Pharma
  11.8.1 Lunan Pharma Company Detail
  11.8.2 Lunan Pharma Business Overview
  11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
  11.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2017-2022)
  11.8.5 Lunan Pharma Recent Development

13 REPORT CONCLUSION

14 DISCLAIMER



More Publications